416 related articles for article (PubMed ID: 6821629)
1. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
Struck RF; Dykes DJ; Corbett TH; Suling WJ; Trader MW
Br J Cancer; 1983 Jan; 47(1):15-26. PubMed ID: 6821629
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.
Struck RF; Schmid SM; Waud WR
Cancer Chemother Pharmacol; 1994; 34(3):191-6. PubMed ID: 8004750
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. I. Antitumour effect of cyclophosphamide and ifosfamide enantiomers.
Paprocka M; Kuśnierczyk H; Budzyński W; Rak J; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1986; 34(3):275-84. PubMed ID: 3592931
[TBL] [Abstract][Full Text] [Related]
4. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.
Lind MJ; Roberts HL; Thatcher N; Idle JR
Cancer Chemother Pharmacol; 1990; 26(2):105-11. PubMed ID: 2347037
[TBL] [Abstract][Full Text] [Related]
5. Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide.
Bryant BM; Jarman M; Baker MH; Smith IE; Smyth JF
Cancer Res; 1980 Dec; 40(12):4734-8. PubMed ID: 7438105
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics and metabolism of ifosfamide during bolus and infusional administration: a randomized cross-over study.
Singer JM; Hartley JM; Brennan C; Nicholson PW; Souhami RL
Br J Cancer; 1998 Mar; 77(6):978-84. PubMed ID: 9528844
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.
Powers JF; Sladek NE
Cancer Res; 1983 Mar; 43(3):1101-6. PubMed ID: 6825082
[No Abstract] [Full Text] [Related]
8. D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport.
Pohl J; Bertram B; Hilgard P; Nowrousian MR; Stüben J; Wiessler M
Cancer Chemother Pharmacol; 1995; 35(5):364-70. PubMed ID: 7850916
[TBL] [Abstract][Full Text] [Related]
9. Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia.
Zaharko DS; Covey JM; Hörpel G
Invest New Drugs; 1984; 2(2):149-54. PubMed ID: 6469508
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
11. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers.
Low JE; Borch RF; Sladek NE
Cancer Res; 1983 Dec; 43(12 Pt 1):5815-20. PubMed ID: 6640533
[TBL] [Abstract][Full Text] [Related]
12. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Lelieveld P; van Putten LM
Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
14. Metabolism of ifosfamide during a 3 day infusion.
Hartley JM; Hansen L; Harland SJ; Nicholson PW; Pasini F; Souhami RL
Br J Cancer; 1994 May; 69(5):931-6. PubMed ID: 8180026
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide in experimental tumor systems.
Goldin A
Semin Oncol; 1982 Dec; 9(4 Suppl 1):14-23. PubMed ID: 6761864
[No Abstract] [Full Text] [Related]
17. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates.
Kuśnierczyk H; Radzikowski C; Paprocka M; Budzyński W; Rak J; Kinas R; Misiura K; Stec W
J Immunopharmacol; 1986; 8(4):455-80. PubMed ID: 3805744
[TBL] [Abstract][Full Text] [Related]
19. Combinations of mesna with cyclophosphamide or adriamycin in the treatment of mice with tumors.
Bernacki RJ; Bansal SK; Gurtoo HL
Cancer Res; 1987 Feb; 47(3):799-802. PubMed ID: 3100025
[TBL] [Abstract][Full Text] [Related]
20. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard.
Boal JH; Williamson M; Boyd VL; Ludeman SM; Egan W
J Med Chem; 1989 Aug; 32(8):1768-73. PubMed ID: 2754703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
